Answers are grounded in this paper and cite their sources.
Randomized trial evaluates the immune response to a bivalent vaccine in adults, suggesting broad protection against Salmonella Paratyphi A.
Background In a first-in-human phase-1, randomized, controlled trial, a bivalent conjugate vaccine (Vi-CRM197+O:2 CRM197) elicited robust IgG and bactericidal activity against vaccine-homologous Salmonella Paratyphi A strain. To further characterize the immune response, we assessed O:2 antigen-specific IgA and IgM responses as markers of mucosal immunity and early immune activation, and evaluated serum bactericidal activity against diverse S. Paratyphi A isolates. Method The trial (NCT05613205) was conducted in three steps. For this exploratory analysis, 46 participants (mean age 27.2 years; 67.4% women) from Step-2 who received two full doses of Vi-CRM197+O:2 CRM197 vaccine with and without Alum (Aluminum hydroxide) 169 days apart were considered. O:2-specific IgA/IgM responses and bactericidal antibodies were assessed. Geometric mean titers and concentrations, and within-participant geometric mean ratios were calculated. Results Both formulations induced strong anti-O:2 IgA/IgM responses and bactericidal activity, with higher responses in the non-adjuvanted group. At Day-29 post-dose 1, IgA rose 74.14- and 16.65-fold (without vs. with Alum), remaining well above baseline through Day-197. The non-adjuvanted formulation induced significantly higher IgA responses and bactericidal activity at Day-29 (p <0.05). Anti-O:2 IgM strongly correlated with bactericidal antibodies against homologous and heterologous strains. Conclusion The vaccine effectively induced O:2-specific IgA, IgM, and bactericidal antibodies against diverse S. Paratyphi A isolates, indicating potential broad protection.
No takes yet. Share an insight, caveat, or question.
Carducci et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: